Is skin rash a common side effect of Uterine Cancer treatment? How can it be managed?

Skin rash can occur during uterine (endometrial) cancer treatment and is relatively common, especially with certain drug combinations and immunotherapy; it can also happen after radiation therapy. Rashes range from mild redness and itch to more significant blistering or peeling, and prior radiation can make drug‑related rashes worse in treated areas. ^{[1] [2]} Skin reactions from anti‑cancer drugs most often appear as a maculopapular (flat and bumpy) rash, and while rare, severe reactions like Stevens‑Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN) can occur and require urgent care. ^{[3] [4]}

What treatments commonly cause rash

• Chemotherapy plus immunotherapy (checkpoint inhibitors): Regimens such as carboplatin + paclitaxel with durvalumab or dostarlimab often list rash, itch (pruritus), blisters, and even full‑thickness skin changes as possible immune‑related side effects; radiation recall (rash at a previously irradiated site) can also happen. ^{[5] [6]} Skin toxicity is among the more frequent immune‑related adverse events with checkpoint inhibitors. ^{[7] [8]}
• Chemotherapy alone: Platinum agents and taxanes can cause drug rashes and, rarely, severe hypersensitivity reactions. Maculopapular rash is the most common drug‑induced pattern across many anti‑cancer medicines. ^{[4] [9]}
• Radiation therapy: Pelvic radiotherapy can lead to radiation‑induced dermatitis (skin inflammation) that typically develops during treatment and may persist for weeks; management follows graded, stepwise care. ^{[10] [11]}

How to recognize and when to act

• Typical features: Red or bumpy rash, dry and itchy skin, peeling, or blisters; effects can be worse in areas previously irradiated. ^{[12] [13]}
• Urgent signs: Worsening pain, fever, open sores, pus, rapidly spreading redness, large blisters, or skin detachment may indicate severe reactions (e.g., SJS/TEN) and need immediate medical attention; re‑exposure to the causative drug should be avoided in such cases. ^[4]
• Report changes early: If the rash becomes painful, oozes, or spreads, contact your care team promptly so treatment can be adjusted. ^{[14] [15]}

Practical management strategies

General skin care (all treatments)

• Gentle moisturizers: Use non‑perfumed creams (e.g., sorbolene or aqueous cream) regularly to reduce dryness and itch. ^{[12] [13]}
• Avoid irritants: Do not scratch; wear loose clothing; limit friction on affected areas. ^{[14] [15]}
• Sun protection: Wear protective clothing, a wide‑brimmed hat, and high‑SPF sunscreen to prevent worsening. ^{[14] [15]}

Over‑the‑counter options

• Topical steroids: Low to medium potency (e.g., hydrocortisone 1%) can reduce inflammation when the skin is intact, especially with radiation dermatitis. ^[11]
• Antihistamines: Can help itching and improve comfort if advised by your clinician. ^{[14] [15]}

During radiation therapy

• Start moisturizing early: If you’re likely to react, begin a moisturizer on day one of radiotherapy to minimize dermatitis. ^{[16] [17]}
• Gentle cleansing: Daily showering with mild, unscented soap; avoid hot water and harsh scrubbing. ^[18]
• Protective habits: Wear loose cotton, avoid adhesive tapes, and use an electric razor if shaving is necessary. ^{[19] [20]}

Managing immune‑related rashes

• Early reporting and graded care: Immune‑related skin toxicities may require topical steroids, oral antihistamines, and sometimes temporary immunotherapy holds; severe cases need systemic steroids and specialist input. These rashes are among the more frequent immune side effects of checkpoint inhibitors used in endometrial cancer. ^{[7] [8]} Care teams follow established immune‑toxicity pathways to prevent progression and protect skin integrity. ^{[5] [21]}

---

Quick comparison: rash patterns and care

Treatment type	Common rash features	First-line care	When to escalate
Chemotherapy (platinum/taxane)	Maculopapular rash, pruritus; rare severe hypersensitivity (SJS/TEN)	Moisturizers, antihistamines, topical steroids if intact skin	Fever, blisters, skin peeling/detachment → urgent care; consider drug hold/adjustment [4]
Immunotherapy (durvalumab/dostarlimab)	Rash, itch, blisters; radiation recall at prior RT sites	Topical steroids, antihistamines; monitor closely	Ulceration, full‑thickness changes → systemic steroids, therapy hold; specialist review [5] [6]
Radiation therapy (pelvis)	Radiation dermatitis in treated field	Gentle cleansing, regular moisturizers, low‑potency topical steroids	Moisture‑associated damage, open wounds, severe pain → wound care protocols and clinician review [11] [16] [18]

---

Safety tips and follow‑up

• Start skin care early and be consistent: Preventive moisturizing and sun protection can reduce severity. ^{[16] [19]}
• Send photos if asked: Care teams may request images to assess severity and guide treatment between visits. ^[22]
• Know severe warning signs: Systemic symptoms (fever, malaise) before a severe rash, rapid spread, or oozing warrant urgent contact with your team to prevent complications. ^{[23] [22]}

---

Key takeaways

• Yes skin rashes are possible across uterine cancer treatments, particularly with chemotherapy–immunotherapy combos and radiation. ^{[1] [2]}
• Most rashes are manageable with moisturizers, topical steroids, antihistamines, and protective habits; early reporting helps prevent worsening. ^{[12] [14] [11]}
• Serious reactions are uncommon but require immediate medical attention and treatment adjustment. ^[4]